Sponsored by:

Business in the Burbs

Movers, shakers and newsmakers

Regeneron begins drug testing program for gout patients


Regeneron Pharmaceuticals Inc., a biotech company in Eastview, said that it has started a testing program to evaluate the effectiveness of its Arcalyst drug as a treatment for gout.

Regeneron said that it expected to release preliminary results of the tests in 2010. The testiing program will involve hundreds of patients.

“Nearly one and a half million Americans are treated for gout each year, but significant unmet medical needs persist,” Dr. George D. Yancopoulos, president of Regeneron Research Laboratories, said in a written statement.

Arcalyst, Regeneron’s only marketable drug, was approved last year for treatment of a rare auto-inflammatory condition known as CAPS.

This entry was posted on Wednesday, March 25th, 2009 at 3:15 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical



About this blog
Business in the Burbs is our online news blog about businesses based or operating in the Lower Hudson Valley. Visitors here will also find items of interest to consumers in the region. Most contributions are from business reporters and editors covering Westchester, Rockland and Putnam counties.


Get blog updates via email:

About the Authors


Other recent entries


Monthly Archives